Dow Jones

52 925,15

-0,25%

Germany 40

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Allemagne
TG
Chemed Corp (CXM)
Chemed Corp (CXM) Actualités

Chemed Corp (CXM)

426,00

0,00

( 0,00% )

Mis à jour : 10:21:01

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided...

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to launch a new premium advanced skin...

Cardium Reports on Exchange Listing With NYSE AMEX

SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the...

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the...

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501...

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue...

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter...

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket...

Cardium Completes $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously...

Cardium Announces $6.0 Million Registered Direct Offering

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock...

Positive Findings from Excellarate(TM) Phase 1/2 Clinical Study Published in Journal of Wound Repair and Regeneration

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the publication of positive findings from the...

Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct

Important Clinical Findings Provide New Therapeutic Insights into Healing Potential of Cardium's Matrix Technology Platform SAN DIEGO, Oct. 14...

Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and

Excellarate Offers Potential for Simpler and Enhanced Treatment Opportunities within the Spectrum of Advanced Wound Care Biologics, Bio-Engineered...

Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study fo

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced plans to report on preliminary safety and efficacy...

Cardium Announces $4.5 Million Common Stock Private Placement

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a common stock private placement to selected...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Axiom Balanced Growth Po...

iShares Transition Enabl...

2.83% 28apr2047 2.83% 28...

Ubs Ag London Branch Aut...

TSX

XTRA.WT

Xtract One Technologies

EU

CEAAH

0.2%until 05nov35 0.2%un...

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Chemed Corp (CXM)

Outils de qualité professionnelle, pour des investisseurs individuels.

Chemed Corp (CXM) Actualités

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

Positive Findings from Excellarate(TM) Phase 1/2 Clinical Study Published in Journal of Wound Repair and Regeneration

Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct

Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and

Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study fo

Cardium Announces $4.5 Million Common Stock Private Placement

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Chemed Corp (CXM)

Outils de qualité professionnelle, pour des investisseurs individuels.

Chemed Corp (CXM) Actualités

Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Ther

Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Com

Cardium Reports on Exchange Listing With NYSE AMEX

Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabe

Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development

Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable

Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments

Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressu

Cardium Completes $6.0 Million Registered Direct Offering

Cardium Announces $6.0 Million Registered Direct Offering

Positive Findings from Excellarate(TM) Phase 1/2 Clinical Study Published in Journal of Wound Repair and Regeneration

Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct

Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and

Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study fo

Cardium Announces $4.5 Million Common Stock Private Placement

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités